Purpose. Epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer has
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …

Molecularly targeted and immunotherapies have improved the care of patients with lung
cancers. These successes have rallied calls to replace or avoid chemotherapy. Yet, even in …

Background Lung cancer is the leading cause of cancer-related death worldwide. Numerous
studies have been performed to investigate the correlation between epidermal growth factor …

ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …

Background The evaluation of the proportional hazards (PH) assumption in survival analysis
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …

Ten years ago, somatic mutations in EGFR were identified in patients with non-small-cell
lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …